1. New clinical guideline recommends statin therapy for adults with HIV to prevent atherosclerotic cardiovascular disease (ASCVD).
2. REPRIEVE trial demonstrated pitavastatin's significant reduction in major cardiovascular events in this population.
3. Statin therapy is recommended for patients with a 10-year ASCVD risk of at least 5%.
4. Careful selection of statins is advised due to potential interactions with antiretroviral medications.
5.  Recommended moderate-intensity statin therapy includes pitavastatin 4 mg, atorvastatin 20 mg, or rosuvastatin 10 mg for patients with HIV and an ASCVD risk between 5% and 20%.
6. The guideline underlines the need for clinician-patient discussions, especially in low-risk cases.
7. Adverse events were noted, but the benefits of statin therapy outweigh the risks, particularly in those at higher cardiovascular risk.
8. This marks the first U.S. guideline to specifically endorse statins for primary prevention of cardiovascular disease in patients with HIV.

Source: Annals of Internal Medicine